Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 3/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL424565 | 0.91 | CA12 (0.56) | CA12CA9CA2CTSLKMT2A | |
| SCHEMBL10176320 | 0.86 | CA12 (0.51) | CA12CA9CA2CTSLKMT2A | |
| SCHEMBL13790752 | 0.80 | CA12 (0.44) | CA12CA9CA2CTSLNR1H2 | |
| SCHEMBL3558164 | 0.78 | CA12 (0.78) | CA12CA9CA2KMT2AACLY | |
| SCHEMBL10176179 | 0.75 | CA12 (0.51) | CA12CA9CA2CTSLKMT2A | |
| SCHEMBL3433282 | 0.73 | CA12 (0.60) | CA12CA9CA2CTSLKMT2A | |
| SCHEMBL6867245 | 0.73 | CA12 (0.54) | CA12CA9CA2KMT2ARECQL | |
| SCHEMBL28017014 | 0.72 | CA12 (0.69) | CA12CA9CA2KMT2ANR1H2 | |
| SCHEMBL425798 | 0.72 | CA12 (0.58) | CA12CA9CA2ACLYRECQL | |
| SCHEMBL10176172 | 0.72 | CA12 (0.58) | CA12CA9CA2CTSLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022121-A1 | INDOLES, DERIVATIVES AND ANALOGS THEREOF AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022121-A1 | INDOLES, DERIVATIVES AND ANALOGS THEREOF AND USES THEREFOR | TUBB, TUBB3, TUBB1 | CA12 4374/4885CA9 4149/4885CA2 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.